Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | CPA2 | P48052 | 1/20 | 0.46 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.46 |
| ▸ | FURIN | P09958 | 6/20 | 0.45 |
| ▸ | NMT2 | O60551 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394605 | 0.89 | SIRT6 (0.56) | SIRT6SIRT1CA1CA2TLR2 | |
| SCHEMBL29396101 | 0.88 | SIRT6 (0.55) | SIRT6SIRT1CA1CA2TLR2 | |
| SCHEMBL10609149 | 0.86 | SIRT6 (0.53) | SIRT6SIRT1CA1CA2TLR2 | |
| SCHEMBL18916662 | 0.86 | SIRT6 (0.57) | SIRT6SIRT1CA1CA2TLR2 | |
| SCHEMBL30598012 | 0.86 | SIRT6 (0.53) | SIRT6SIRT1CA1CA2TLR2 | |
| SCHEMBL29398096 | 0.85 | GNPAT (0.53) | SIRT6SIRT1CPA1CPA2CPA4 | |
| D-Alanine SCHEMBL5702807 | 0.85 | SIRT6 (0.52) | SIRT6SIRT1CA1CA2TLR2 | |
| SCHEMBL10888019 | 0.84 | SIRT6 (0.51) | SIRT6SIRT1CA1CA2TLR2 | |
| SCHEMBL17787396 | 0.83 | NMT2 (0.52) | SIRT6SIRT1CA1CA2TLR2 | |
| SCHEMBL12749404 | 0.83 | SIRT6 (0.58) | SIRT6SIRT1CA1CA2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | CURIA BUFFALO R&D, LLC | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151232-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OPIOID ABUSE | OPRM1, OPRK1, OPRD1 | SIRT6 2079/4885SIRT1 1554/4885CA1 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.